Immunology and immunotherapy of human cancer: Present concepts and clinical developments

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 1, 2000, Pages 1-25

  Bremers, Andreas J A ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Human cancers; Immunology; Immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER ANTIBODY; CANCER VACCINE; CYTOKINE; HEAT SHOCK PROTEIN; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERFERON; INTERLEUKIN 2; LEVAMISOLE; PICIBANIL; RECOMBINANT VACCINE; SODIUM DITHIOCARBONATE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; BLADDER CANCER; BREAST CANCER; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL LYSATE; CLINICAL TRIAL; COLON CANCER; DENDRITIC CELL; DRUG EFFICACY; GENETIC MANIPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MOLECULAR RECOGNITION; NATURAL KILLER CELL; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR RESISTANCE; VACCINATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

EID: 0034002950     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00059-1     Document Type: Review

References (215)

1. Coley W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hospital. 7:1896;157.
2. Ehrlich P. Üer den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneesk. 53:1909;273-290.
3. Hellstrom I., Hellstrom K.E. Tumor vaccines: a reality at last? J Immunother. 21:1998;119-126.
4. Rosenberg S.A., Kawakami Y., Robbins P.F. et al. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res. 70:1996;145-177.
5. Boon T., van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 183:1996;725-729.
6. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr Op Immunol. 10:1998;588-594.
7. Bremers A.J., van der Burg S.H., Kuppen P.J. et al. The use of Epstein-Barr virus-transformed b lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. J Immunother Emphasis Tumor Immunol. 18:1995;77-85.
8. Chang M.H., Chen C.J., Lai M.S. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Eng J Med:-1859. 336:1855;1997.
9. Ressing M.E., van Driel W.J., Celis E. et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen A*0201-restricted E7-encoded epitope. Cancer Res. 56:1996;582-588.
10. Toes R.E.M., Ossendorp F., Offringa R. et al. CD4 T cells and their role in antitumor immune responses. J Exp Med. 189:1999;753-756.
11. Davis M.M., Boniface J.J., Reich Z. et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 16:1998;523-544.
12. Huang A.Y., Golumbek P., Ahmadzadeh M. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
13. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
14. Adema G.J., Hartgers F., Verstraten R. et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 387:1997;713-717.
15. Gong J., Chen D., Kashiwaba M. et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med: 5. 3:1997;58-561.
16. Toes R.E., van der Voort E.I., Schoenberger S.P. et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol. 160:1998;4449-4456.
17. Colaco C.A. Why are dendritic cells central to cancer immunotherapy? Mol Med Today. 5:1999;14-17.
18. Moretta A., Bottino C., Vitale M. et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 14:1996;619-648.
19. Trowsdale J., Travers P., Bodmer W.F. et al. Expression of HLA-A,-B, and-C and beta 2-microglobulin antigens in human choriocarcinoma cell lines. J Exp Med: s. 152:1980;11s-17.
20. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 16:1995;487-494.
21. Kos F.J. Regulation of adaptive immunity by natural killer cells. Immunol Res. 17:1998;303-312.
22. Roncarolo M.G., Bigler M., Haanen J.B.A. et al. Natural Killer cell clones can efficiently process and present protein antigens. J Immunol. 147:1991;781-787.
23. Houbiers J.G., van der Burg S.H., van de Watering L.M. et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 72:1995;637-641.
24. Disis M.L., Cheever M.A. Oncogenic proteins as tumor antigens. Curr Opin Immunol. 8:1996;637-642.
25. Koda K., Nakajima N., Saito N. et al. A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Br J Cancer. 78:1998;1313-1322.
26. Hsueh E.C., Gupta R.K., Qi K. et al. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am. 3:1997;364-370.
27. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 18:1957;769-778.
28. van Duinen S.G., Ruiter D.J., Broecker E.B. et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 48:1988;1019-1025.
29. Hicklin D.J., Wang Z., Arienti F. et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 101:1998;2720-2729.
30. Clemente C., Mihm M.C., Bufalino R. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 77:1996;1303-1310.
31. Rosenberg S.A., White D.E. Brief report vitiligo in patients with melanoma: normal tissue antigens can be targets for canceer immunotherapy. J Immunother. 19:1996;81-84.
32. Naito Y., Saito K., Shiiba K. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor factor in human colorectal cancer. Cancer Res. 58:1998;3491-3494.
33. McMillan D.C., Fyffe G.D., Wotherspoon H.A. et al. Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer. Dis Colon Rectum. 40:1997;1068-1071.
34. Diederichsen A.C., Ostenhom A.C., Kronborg O. et al. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer. 79:1998;283-287.
35. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res. 13:1970;1-27.
36. Penn I. Depressed immunity and the development of cancer. Cancer Detection & Prevention. 18:1994;241-252.
37. Uyttenhove C., Maryanski J., Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med. 157:1983;1040-1052.
38. Jager E., Ringhoffer M., Karbach J. et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 66:1996;470-476.
39. Maeurer M.J., Gollin S.M., Martin D. et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 98:1996;1633-1641.
40. Kageshita T., Hirai S., Ono T. et al. Down-regulation of HLA Class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 154:1999;745-754.
41. Torre-Amione G., Beauchamp R.D., Koeppen H. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA. 87:1990;1486-1490.
42. Hahne M., Rimoldi D., Schroter M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
43. Gratas C., Tohma Y., Van Meir E.G. et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7:1997;863-869.
44. O'Connell J., O'Sullivan G.C., Collins J.K. et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 184:1996;1075-1082.
45. Niehans G.A., Brunner T., Frizelle S.P. et al. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
46. Rabinowich H., Reichert T.E., Kashii Y. et al. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest. 101:1998;2579-2588.
47. Bennett M.W., O'Connell J., O'Sullivan G.C. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 160:1998;5669-5675.
48. Pitti R.M., Marsters S.A., Lawrence D.A. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703.
49. Rivoltini L., Radrizzani M., Accornero P. et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol. 161:1998;1220-1230.
50. Speiser D.E., Miranda R., Zakarian A. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 186:1997;645-653.
51. Wick M., Dubey P., Koeppen H. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 186:1997;229-238.
52. Habicht A., Lindauer M., Galmbacher P. et al. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer. 31A:1995;2396-2402.
53. Staveley-O'Carroll K., Sotomayor E., Montgomery J. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA. 95:1998;1178-1183.
54. Paglia P., Guzman C.A. Keeping the immune system alerted against cancer. Cancer Immunol Immunother. 46:1998;88-92.
55. Ressing ME, van Driel WJ, Brandt MP, et al. Detection of immune responses to helper peptide, but not to viral CTL epitopes, following peptide vaccination of immunocompromised patients with recurrent cervical carcinoma, (in press).
56. Kim J.P., Kwon O.J., Oh S.T. et al. Results of surgery of 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg. 216:1992;269-278.
57. Schlag P., Manasterski M., Gerneth T. et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother. 35:1992;325-330.
58. Dufour P., Lang J.M., Giron C. et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 6:1993;9-12.
59. Rosenberg S.A., Lotze M.T., Yang J.C. et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 210:1989;474-485.
60. Stouthard J.M., Goey H., de Vries E.G. et al. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer. 73:1996;789-793.
61. Bukowski R.M., Olencki T., Wang Q. et al. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J Immunother. 20:1997;301-311.
62. Schiller J.H., Storer B.E., Witt P.L. et al. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res. 51:1991;1651-1658.
63. Ruegg C., Yilmaz A., Bieler G. et al. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculation induced by TNF and IFN-γ Nature Med. 4:1998;408-414.
64. de Vries M.R., Rinkes I.H., van de Velde C.J. et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Rec Res Cancer Res. 147:1998;107-119.
65. Golumbek P.T., Azhari R., Jaffee E.M. et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53:1993;5841-5844.
66. Nooijen P.T., Eggermont A.M., Schalkwijk L. et al. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 58:1998;4880-4887.
67. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Op Immunol. 9:1997;10-16.
68. Anichini A., Mortarini R., Maccalli C. et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol. 156:1996;208-217.
69. Aichele P., Brduscha-Riem K., Zinkernagel R.M. et al. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med. 182:1995;261-266.
70. Kast W.M., Roux L., Curren J. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA. 88:1991;2283-2287.
71. Feltkamp M.C., Smits H.L., Vierboom M.P. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
72. Lee K.H., Panelli M.C., Kim C.J. et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol. 161:1998;4183-4194.
73. Minev B.R., McFarland B.J., Spiess P.J. et al. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:1994;4155-4161.
74. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
75. Bronte V., Tsung K., Rao J.B. et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 154:1995;5282-5292.
76. Hoiseth S.K., Stocker B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:1981;238-239.
77. Stover C.K., de la Cruz V.F., Fuerst T.R. et al. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
78. Schafer R., Portnoy D.A., Brassell S.A. et al. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol. 149:1992;53-59.
79. Pan Z.K., Ikonomidis G., Lazenby A. et al. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med. 1:1995;471-477.
80. Irvine K.R., Chamberlain R.S., Shulman E.P. et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst USA. 89:1997;1595-1601.
81. Pardoll D.M., Beckerleg A.M. Exposing the immunology of naked DNA vaccines. Immunity. 3:1995;165-169.
82. Fu T.M., Ulmer J.B., Caulfield M.J. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 3:1997;362-371.
83. Livingston P.O. Augmenting the immunogenicity of carbohydrate tumor antigens. Sem Cancer Biol. 6:1995;357-366.
84. Nair S.K., Boczkowski D., Snyder D. et al. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol. 27:1997;589-597.
85. Hsu F.J., Benike C., Fagnoni F. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2:1996;52-58.
86. Tjoa B., Erickson S., Barren R. et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate. 27:1995;63-69.
87. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
88. Boczkowski D., Nair S.K., Snyder D. et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 184:1996;465-472.
89. Specht J.M., Wang G., Do M.T. et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med. 186:1997;1213-1221.
90. Caux C., Liu Y.J., Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today. 16:1995;2-4.
91. Nestle F.O., Alijagic S., Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4:1998;328-332.
92. Thurnher M., Ramoner R., Gastl G. et al. Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int J Cancer. 70:1997;128-134.
93. Itaya T., Yamagiwa S., Okada F. et al. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Res. 47:1987;3136-3140.
94. Plautz G.E., Yang Z.Y., Wu B.Y. et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA. 90:1993;4645-4649.
95. Colombo M.P., Forni G. Cytokine gene transfer strategies. Cancer Met Rev. 15:1996;317-328.
96. Sule-Suso J., Arienti F., Melani C. et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol. 25:1995;2737-2742.
97. Parmiani G., Colombo M.P., Melani C. et al. Cytokine gene transduction in the immunotherapy of cancer. Adv Pharmacol. 40:1997;259-307.
98. Dranoff G., Jaffee E., Lazenby A. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
99. Srivastava P.K., Heike M. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Sem Immunol. 3:1991;57-64.
100. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269:1995;1585-1588.
101. Tamura Y., Peng P., Liu K. et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:1997;117-120.
102. Melcher A. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. 4:1998;581-587.
103. Hsueh E.C., Nathanson L., Foshag L.J. et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer. 85:1999;2160-2169.
104. Vermorken J.B., Claessen A.M., van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 353:1999;345-350.
105. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 183:1996;2533-2540.
106. Kwon E.D., Hurwitz A.A., Foster B.A. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA. 94:1997;8099-8103.
107. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H. et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 91:1998;1083-1090.
108. Smit W.M., Rijnbeek M., van Bergen C.A. et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA. 95:1998;10152-10157.
109. Shetye J., Ragnhammar P., Liljefors M. et al. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res:-1929. 4:1921;1998.
110. Stockmeyer B., Valerius T., Repp R. et al. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res. 57:1997;696-701.
111. Katsumata M., Okudaira T., Samanta A. et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nature Med. 1:1995;644-648.
112. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 45:1997;210-215.
113. Krege S., Giani G., Meyer R. et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin. Participating Clinics. J Urol. 156:1996;962-966.
114. Lamm D.L., Blumenstein B.A., Crawford E.D. et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Eng J Med. 325:1991;1205-1209.
115. Veronesi U., Adamus J., Aubert C. et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Eng J Med. 307:1982;913-916.
116. Tan J.K., Ho V.C. Pooled analysis of the efficacy of Bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermat Surg Oncol. 19:1993;985-990.
117. Moertel C.G., Fleming T.R., MacDonald J.S. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Eng J Med. 322:1990;352-356.
118. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer, Lancet 1995;345:939-944.
119. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer, J Am Med Assoc 1990;264:1444-1450.
120. Migdley R., Kerr D. Colorectal cancer. Lancet. 353:1999;391-399.
121. Takahashi K., Harauchi D., Kimura S. et al. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int J Immunopharm. 20:1998;375-388.
122. Kim J.-P., Kim Y.-W., Yang H.-K. et al. Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients. World J Surg. 18:1994;872-878.
123. Kirkwood J.M., Wilson J., Whiteside T.L. et al. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanomal. Cancer Immunol Immunother. 44:1997;137-149.
124. Isenberg J., Stoffel B., Wolters U. et al. Immunostimulation by propionibacteria- Effects on immune status and antineoplastic treatment. Anticancer Res. 15:1995;2363-2368.
125. Rosenberg S.A., Yang J.C., White D.E. et al. Durability of complete responses in patients with metastatic cancer treated with highdose interleukin2: identification of the antigens mediating response. Ann Surg. 228:1998;307319.
126. Kirkwood J.M., Strawderman M.H., Ernstoff M.S. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 14:1996;7-17.
127. Kirkwood J.M., Ibrahim J., Sondak V. et al. Preliminary analysis pf the E1690/C9190 Intergroup Postoperative Adjuvant Trial of high- and low-dose IFN-α2b (HDI and LDI) in high-risk primary of lymph node metastatic melanoma. Proc Am Soc Clin Oncol. 18(2072):1999;537a.
128. Pehamberger H., Soyer H.P., Steiner A. et al. Adjuvant interferon alfa2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 16:1998;1425-1429.
129. Grob J.J., Dreno B., de la Salmoniere P. et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 351:1998;1905-1910.
130. Eggermont A.M. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs. Melanoma Res. 7:1997;S127-S131.
131. Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 338:1998;1272-1278.
132. Medical Research Council Renal Cancer Collaborators. Interferon alpha and survival in metastatic renal carcinoma: early results of a controlled trial, Lancet 1999;353:1417.
133. Ellerhorst J.A., Kilbourn R.G., Amato R.J. et al. Phase II trial of low dose gammainterferon in metastatic renal cell carcinoma. J Urol. 152:1994;841-845.
134. Brown T.D., Goodman P.J., Fleming T. et al. Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. J Immunother. 10:1991;379-382.
135. Motzer R.J., Rakhit A., Schwartz L.H. et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 4:1998;1183-1191.
136. Bajetta E., Del Vecchio M., Mortarini R. et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma Recognition of melanoma derived antigens by CTL: possible mechanisms involved in downregulating antitumor T-cell reactivity. Clin Cancer Res. 18:1998;5563.
137. Atkins M.B., Robertson M.J., Gordon M. et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 3:1997;409417.
138. Rini B.I., Stadler W.M., Spielberger R.T. et al. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 82:1998;1352-1358.
139. Keilholz U., Stoter G., Punt C.J. et al. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am. 3:1997;S22-S28.
140. Dutcher J.P., Atkins M., Fisher R. et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am. 3:1997;S73-S78.
141. Atzpodien J., Lopez Hanninen E., Kirchner H. et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 13:1995;497-501.
142. Lissoni P., Barni S., Ardizzoia A. et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori. 79:1993;397-400.
143. Vogelzang N.J., Lipton A., Figlin R.A. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol. 11:1993;1809-1816.
144. Bergmann L., Fenchel K., Weidmann E. et al. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer. 72:1993;1733-1742.
145. Veelken H., Rosenthal F.M., Schneller F. et al. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotechnol Ther. 3:1992;1-14.
146. Stadler W.M., Kuzel T., Dumas M. et al. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 16:1998;1820-1825.
147. Chang A.E., Cameron M.J., Sondak V.K. et al. A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma. J Immunother Emphasis Tumor Immunol. 18:1995;253-262.
148. Keilholz U., Scheibenbogen C., Brossart P. et al. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma. Rec Res Cancer Res. 139:1995;383-390.
149. Creagan E.T., Rowland Jr K.M., Suman V.J. et al. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. Am J Clin Oncol. 20:1997;490-492.
150. Creagan E.T., Hestorff R.D., Suman V.J. et al. Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study. Am J Clin Oncol. 21:1998;139-141.
151. Escudier B., Ravaud A., Berton D. et al. Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. J Immunother. 21:1998;62-64.
152. Lienard D., Eggermont A.M., Kroon B.B. et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Sem Surg Oncol. 14:1998;202-209.
153. Eggermont A.M., Schraffordt Koops H., Klausner J.M. et al. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Sem Oncol. 24:1997;547-555.
154. Alexander H.R., Bartlett D.L., Libutti S.K. et al. Isolated hepatic perfusion with tumor necrosis factor and pelphalan for unresectable cancers confined to the liver. J Clin Oncol. 16:1998;1479-1489.
155. Marchand M., van Baren N., Weynants P. et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219-230.
156. Rosenberg S.A., Yang J.C., Schwartzentruber D.J. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4:1998;321-327.
157. Cormier J.N., Salgaller M.L., Prevette T. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 3:1997;37-44.
158. Jager E., Ringhoffer M., Altmannsberger M. et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 71:1997;142-147.
159. Miles D.W., Towlson K.E., Graham R. et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 74:1996;1292-1296.
160. Finn O.J., Jerome K.R., Henderson R.A. et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 145:1995;61-89.
161. Goydos J.S., Elder E., Whiteside T.L. et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 63:1996;298-304.
162. Kageshita T., Hirai S., Ono T. Clinical trial of anti-idiotypic monoclonal antibodies in advanced melanoma. Jap J Cancer Chemother. 21:1994;163-169.
163. McLaughlin J.P., Schlom J., Kantor J.A. et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56:1996;2361-2367.
164. Borysiewicz L.K., Fiander A., Nimako M. et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
165. Wallack M.K., Sivanandham M., Balch C.M. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 187:1998;69-79.
166. Lytle G.H., McGee J.M., Yamanashi W.S. et al. Five-year survival in breast cancer treated with adjuvant immunotherapy. Am J Surg. 168:1994;19-21.
167. Berd D., Maguire Jr H.C., McCue P. et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 8:1990;1858-1867.
168. Sahasrabudhe D.M., deKernion J.B., Pontes J.E. et al. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinomal. J Biol Resp Mod. 5:1986;581-594.
169. Elliott G.T., McLeod R.A., Perez J. et al. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Sem Surg Oncol. 9:1993;264-272.
170. Berd D., Maguire Jr H.C., Schuchter L.M. et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 15:1997;2359-2370.
171. Repmann R., Wagner S., Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res. 17:1997;2879-2882.
172. Hoover Jr H.C., Brandhorst J.S., Peters L.C. et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 11:1993;390-399.
173. Bremers A.J., Parmiani G. Letter. Immunotherapy for colon cancer. Lancet. 353:1999;1524-1525.
174. Del Vecchio M., Parmiani G. Cancer vaccination. Forum Trends Exp Clin Med. 9:1999;239-256.
175. Abdel-Wahab Z., Weltz C., Hester D. et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. Monitoring the humoral immune response. Cancer. 80:1997;401-412.
176. Tahara H. et al. Antitumor effects in patients with melanoma, head and neck and breast cancer in a phase I/II clinical trial of interleukin-12 (IL-12) gene therapy. Proc Am Ass Cancer Res. 16:1997;438a.
177. Soiffer R., Lynch T., Mihm M. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 95:1998;13141-13146.
178. Simons J.W., Jaffee E.M., Weber C.E. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57:1997;1537-1546.
179. Palmer K., Moore J., Everard M. et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther. 10:1999;1261-1268.
180. Nemunaitis J., Bohart C., Fong T. et al. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 5:1998;292-300.
181. Moller P., Sun Y., Dorbic T. et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer. 77:1998;1907-1916.
182. Arienti F., Sulé-Suso J., Belli F. et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 7:1996;1955-1963.
183. Belli F., Arienti F., Sulé-Suso J. et al. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother. 44:1997;197-203.
184. Lotze M.T., Rubin J.T., Carty S. et al. Clinical protocol: gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther. 5:1994;41-55.
185. Salgaller M.L., Tjoa B.A., Lodge P.A. et al. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol. 18:1998;109-119.
186. Chakraborty N.G., Sporn J.R., Tortora A.F. et al. Immunization with a tumor cell-lysate-loaded autologous antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother. 47:1998;58-64.
187. Gjertsen M.K., Bakka A., Breivik J. et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet. 346:1995;1399-1400.
188. Hennemann B., Beckmann G., Eichelmann A. et al. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother. 45:1998;250-256.
189. Rosenberg S.A., Lotze M.T., Yang J.C. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst USA. 85:1993;622-632.
190. Dillman R.O., Oldham R.K., Barth N.M. et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst USA. 82:1990;1345-1349.
191. Parkinson D.R., Abrams J.S., Wiernik P.H. et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 8:1990;1650-1656.
192. Kimura H., Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 80:1997;42-49.
193. Dillman R.O., Oldham R.K., Tauer K.W. et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 9:1991;1233-1240.
194. Tomita Y, Katagiri A, Saito K et al. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol. 5:1998;16-21.
195. Rosenberg S.A., Yannelli J.R., Yang J.C. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst USA. 86:1994;1159-1166.
196. Arienti F., Belli F., Rivoltini L. et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother. 36:1993;315-322.
197. Dillman R.O., Oldham R.K., Barth N.M. et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer. 68:1991;1-8.
198. Figlin R.A., Pierce W.C., Kaboo R. et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 158:1997;740-745.
199. Figlin R., Gitlitz B., Franklin J. et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 3:1997;S92-S97.
200. Ratto G.B., Zino P., Mirabelli S. et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer. 78:1996;244-251.
201. Wang Y., Chen H., Wu M. et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chinese Med J. 110:1997;114-117.
202. Maccalli C., Farina C., Sensi M. et al. TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients. J Immunol. 158:1997;5902-5913.
203. Yee R., Savage P.A., Lee P.P. et al. Isolation of high avidity melanoma-reactive CTL form heterogenous populations using peptide-MHC tetramers. J Immunol. 162:1999;2227-2234.
204. Canevari S., Stoter G., Arienti F. et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst USA. 87:1995;1463-1469.
205. Valmori D., Pittet M.J., Rimoldi D. et al. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59:1999;2167-2173.
206. Friess H., Gassmann M., Buchler M.W. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol. 21:1997;43-52.
207. Riethmueller G., Holz E., Schlimok G. et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794.
208. van de Winkel J.G., Bast B., de Gast G.C. Immunotherapeutic potential of bispecific antibodies. Immunol Today. 18:1997;562-564.
209. Alvarez R.D., Partridge E.E., Khazaeli M.B. et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 65:1997;94-101.
210. Nasi M.L., Meyers M., Livingston P.O. et al. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res. 7:1997;S155-S162.
211. Hartmann F., Renner C., Jung W. et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 89:1997;2042-2047.
212. Cheung N.K., Kushner B.H., Cheung I.Y. et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 16:1998;3053-3060.
213. McLaughlin P., Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16:1998;2825-2833.
214. Pegram M.D., Lipton A., Hayes D.F. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185Her2/neu monoclonal antibody plus cisplatin in patients with HER2/Neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:1998;2659-2671.
215. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 21:1999;309-318.